Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473150 | 0.84 | HDAC1 (0.40) | MAPK1KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL31473132 | 0.83 | HCRTR1 (0.45) | HCRTR1HCRTR2PDE10A | |
| SCHEMBL31473158 | 0.79 | EHMT2 (0.40) | — | |
| SCHEMBL31473167 | 0.77 | MAPT (0.38) | MAPK1KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL31473144 | 0.74 | HCRTR1 (0.43) | MAPK1HCRTR1HCRTR2KMT2AMEN1 | |
| SCHEMBL31473141 | 0.70 | CAPN1 (0.35) | — | |
| SCHEMBL31473155 | 0.65 | FSHR (0.31) | — | |
| SCHEMBL6841102 | 0.64 | MEN1 (0.41) | KCNH2KMT2AMEN1OPRM1OPRD1 | |
| SCHEMBL31473156 | 0.64 | LMNA (0.37) | MAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL31473157 | 0.64 | CYP2C9 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008784-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES | VASTHERA CO LTD (KR) | 2026-01-08 | — | — | US | disclosed |
| CN-119403810-A | Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases | 瓦斯塞拉股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008784-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES | PRDX1, PRDX2, PRDX6 | BRD4 3303/4885TLR7 1790/4885MAPK1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.